Preclinical Therapeutic Testing
Preclinical Therapeutic Testing - Related Videos
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
0 Views •
Cited by 4 •
2021
Rapid and efficient quantification of intracellular M. tuberculosis growth is crucial for pursuing improved therapies against tuberculosis (TB). This protocol describes a broth-based colorimetric detection assay using an automated liquid culture system to quantify Mtb growth in macrophages treated with candidate host-directed therapies.
08:07
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
0 Views •
Cited by 5 •
2023
This protocol provides methods for generating 3D engineered cardiac and skeletal muscle tissues and describes their use in preclinical drug screening modalities. The described methods utilize a magnetic sensing system to facilitate the simultaneous assessment of 24 tissues in parallel.
07:10
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
0 Views •
Cited by 17 •
2011
A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described. The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.
08:29
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
0 Views •
Cited by 12 •
2014
Established cancer cell lines and xenografts have been the mainstay of cancer research for the past several decades. However, recent evidence suggests that therapeutic response is greatly influenced by the tumor cell microenvironment. Therefore, we have developed an ex vivo analysis of primary tumor specimens for drug development purposes.
FAQs
Dose-response analysis shows how changes in treatment amount relate to biological activity, therapeutic effects, and toxicity. Researchers can compare responses across tested conditions to identify doses that produce useful effects while limiting harmful tissue or developmental outcomes. These findings support refinement of dosing strategies before a candidate advances to clinical research.
Molecular targets indicate whether an intervention affects the biological process it was designed to influence, while tissue effects show how that activity changes cells or organized structures. Considering both levels helps researchers connect mechanism with outcome, assess whether responses are therapeutically meaningful, and identify effects that may signal toxicity or altered development.
Developmental models can show how a treatment changes cell differentiation, tissue formation, disease mechanisms, or recovery from developmental defects. These effects may not be captured by activity or toxicity measurements alone. Including developmental outcomes is therefore important when a therapy could influence forming tissues, cell-state transitions, or processes involved in developmental disease.
Researchers can examine a candidate under controlled conditions in cell cultures, organoids, and animal models, measuring dose responses, molecular targets, tissue effects, toxicity, and developmental outcomes. Using these model systems provides complementary evidence about biological activity and therapeutic effects. The resulting comparisons help prioritize candidates and refine dosing or delivery strategies.
Key measurements include dose response, biological activity, molecular target engagement, tissue effects, toxicity, and developmental outcomes. Together, they show whether a treatment produces the intended effect, at what tested exposure it occurs, and whether harmful changes accompany it. In developmental biology, these measurements also connect treatment response with differentiation, tissue formation, and developmental defects.
Preclinical evidence helps researchers determine whether a candidate has sufficient support for clinical research. Stronger support comes from consistent therapeutic or biological effects alongside acceptable toxicity and relevant developmental findings under controlled conditions. The evidence can also identify risks, prioritize more promising candidates, and guide adjustments to dosing and delivery before human evaluation.